The notices it replaced
- Reissues: PAR-22-071 Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
- 2 steps back: PAR-20-116 Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
Who won it before
22 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $14,238,409 in first-year total cost, median $608,697.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IMST-U (55)]7
- Special Emphasis Panel[ZRG1 MCST-U (55)]7
- Special Emphasis Panel[ZRG1 IMST-A (55)]4
- Special Emphasis Panel[ZRG1 IMST-M (55)]4
Most frequent institutions
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- CEDARS-SINAI MEDICAL CENTER1
- EMORY UNIVERSITY1
- FRED HUTCHINSON CANCER RESEARCH CENTER1
- MASSACHUSETTS GENERAL HOSPITAL1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Translational development of osteosarcoma (OS) extracellular vesicle (EV) matrix metalloproteinase (MMP) Activity Assay for assessing patient treatment responses1R01CA298883-01 · under PAR-22-071 | JONAS, STEVEN JOHNTSENG, HSIAN-RONGZHU, YAZHEN | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $2,097,875 | ZRG1 |
| 2025 | Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer1R01CA298877-01 · under PAR-22-071 | LIU, TRACY WLOVELL, JONATHAN FSHAFIRSTEIN, GAL | STATE UNIVERSITY OF NEW YORK AT BUFFALO, NY | $677,176 | ZRG1 |
| 2024 | Designer extracellular vesicles for cancer therapy1R01CA284182-01A1 · under PAR-22-071 | XU, XIAOWEI | UNIVERSITY OF PENNSYLVANIA, PA | $662,946 | ZRG1 |
| 2024 | Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model1R01CA294557-01 · under PAR-22-071 | LI, YUANPEI | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $634,743 | ZRG1 |
| 2023 | Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors1R01CA264508-01A1 · under PAR-22-071 | DUVALL, CRAIG LEWISRHOADES (STERLING), JULIE A | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $667,924 | ZRG1 |
| 2023 | Chip-Scale Intraoperative Optical Navigation with Immunotargeted Upconverting Nanoparticles1R01CA278672-01A1 · under PAR-22-071 | ANWAR, MEKHAILCOHEN, BRUCE E | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $655,333 | ZRG1 |
| 2023 | Targeted RNA delivery using ribonucleoprotein1R01CA268985-01A1 · under PAR-22-071 | GAO, XIAOHU | UNIVERSITY OF WASHINGTON, WA | $604,082 | ZRG1 |
| 2023 | Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment1R01CA284247-01 · under PAR-22-071 | LJUBIMOV, ALEXANDER V | CEDARS-SINAI MEDICAL CENTER, CA | $577,033 | ZRG1 |
| 2023 | Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy1R01CA284108-01 · under PAR-22-071 | JIANG, WENKIM, BETTY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $567,816 | ZRG1 |
| 2023 | Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors1R37CA278671-01 · under PAR-22-071 | BELLAT, VANESSA | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $511,558 | ZRG1 |
| 2022 | Toward translation of a plant virus-based in situ vaccination nanotechnology1R01CA274640-01 · under PAR-20-116 | FIERING, STEVENRANJAN, ASHISHSTEINMETZ, NICOLE FRANZISKA | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $649,918 | ZRG1 |
| 2022 | Pre-IND Development of Polymeric Micelles with Dual Drug Payloads for HCC Therapy1R01CA257842-01A1 · under PAR-20-116 | CHOW, DIANA S-L.LI, CHUNYANG, PEIYING | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $642,984 | ZRG1 |
| 2022 | Towards Translation of MU-CN29: New Therapeutic Nanoparticle for Drug-Resistant NSCLC1R01CA274677-01 · under PAR-20-116 | KANNAN, RAGHURAMAN | UNIVERSITY OF MISSOURI-COLUMBIA, MO | $622,068 | ZRG1 |
| 2022 | Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma1R01CA274675-01 · under PAR-20-116 | WILSON, JOHN TANNER | VANDERBILT UNIVERSITY, TN | $604,335 | ZRG1 |
| 2021 | High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer1R01CA264363-01 · under PAR-20-116 | CASTRO, CESAR MLEE, HAKHO | MASSACHUSETTS GENERAL HOSPITAL, MA | $662,338 | ZRG1 |
| 2021 | TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION1R01CA264488-01 · under PAR-20-116 | KABANOV, ALEXANDER V | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $613,059 | ZRG1 |
| 2021 | Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancer1R01CA258737-01 · under PAR-20-116 | KRON, STEPHEN J.YEO, YOON | PURDUE UNIVERSITY, IN | $602,006 | ZRG1 |
| 2021 | Rapid and affordable magneto-nanosensors for ctDNA-guided lung cancer management1R01CA257843-01A1 · under PAR-20-116 | WANG, SHAN X. | STANFORD UNIVERSITY, CA | $573,461 | ZRG1 |
| 2021 | Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer1R01CA257851-01 · under PAR-20-116 | KIM, WILLIAM Y.LI, ZIBOXIE, JIN | UNIVERSITY OF GEORGIA, GA | $552,591 | ZRG1 |
| 2021 | Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis1R01CA257861-01 · under PAR-20-116 | YANG, LILY | EMORY UNIVERSITY, GA | $542,085 | ZRG1 |
| 2021 | Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy1R01CA257837-01 · under PAR-20-116 | KWON, GLEN S. | UNIVERSITY OF WISCONSIN-MADISON, WI | $347,945 | ZRG1 |
| 2021 | Developing macrophage reprogramming mRNA nanocarriers for initial clinical testing1R01CA263524-01 · under PAR-20-116 | STEPHAN, MATTHIAS | FRED HUTCHINSON CANCER RESEARCH CENTER, WA | $169,133 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.